Date: 2015-06-15
Type of information: Nomination
Compound:
Company: Bluebird bio (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases - Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 15, 2015, bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, announced that Philip Gregory, D. Phil., is joining the company as its Chief Scientific Officer and a member of the leadership team. Dr. Gregory comes to bluebird bio from Sangamo BioSciences Inc., where he most recently served as Chief Scientific Officer and Senior Vice President, Research. At Sangamo, Dr. Gregory was responsible for setting the scientific direction of the company, prosecuting the development of the company’s genome editing platform and overseeing the early discovery and development of IND candidates. Dr. Gregory holds a D.Phil. in Biochemistry from Oxford University, and B.Sc. in Microbiology from Sheffield University.
Financial terms:
Latest news:
